Acetyl Tetrapeptide-3
Hair / GrowthAlso known as: Capixyl Component, Biomimetic Peptide
Mechanism
An anti-hair-loss peptide that works by reducing the damaging effects of DHT (the hormone that shrinks hair follicles in pattern baldness). It's the key active in Capixyl, a popular hair growth complex that combines it with red clover extract. Helps reduce hair miniaturization — the progressive thinning that occurs in androgenetic alopecia.
Technical detail
Acetylated tetrapeptide that inhibits local 5-alpha reductase activity in the dermal papilla, reducing conversion of testosterone to dihydrotestosterone (DHT) at the follicular level. DHT binds androgen receptors in susceptible follicles, activating TGF-beta1/2 and DKK-1, leading to follicle miniaturization. Acetyl Tetrapeptide-3 also directly stimulates extracellular matrix proteins (collagen III, laminin-5) in the dermal papilla, anchoring the hair bulb. Component of Capixyl (Lucas Meyer Cosmetics): combined with Biochanin A (4'-methylgenistein) from red clover — an isoflavone that also inhibits 5-alpha reductase. Clinical trial: 46% reduction in hair loss vs. 33% with minoxidil 5%.
Effects
## Integumentary/Hair Follicle System [Tier 2 - In Vitro/Small Human Studies] - Biomimetic peptide that modulates hair follicle extracellular matrix (ECM) remodeling - Inhibits 5-alpha-reductase activity, reducing local DHT (dihydrotestosterone) production at the follicle level - Anti-5AR activity is significantly weaker than finasteride but occurs locally without systemic antiandrogen effects - Reduces expression of TGF-beta (transforming growth factor beta), which drives follicular miniaturization in androgenetic alopecia - Part of the Capixyl complex (acetyl-tetrapeptide-3 + red clover extract containing biochanin A) ## Dermal Papilla/Stem Cell [Tier 2 - In Vitro Data] - Increases size and proliferation of dermal papilla cells in culture (dermal papilla size correlates with hair thickness) - Enhances ECM protein expression (collagen, fibronectin, laminin) that anchors the hair bulb - Reduces MMP (matrix metalloproteinase) activity that degrades the follicular ECM during AGA progression - Promotes hair follicle stem cell activation by improving the stem cell niche microenvironment ## Anti-Inflammatory/Follicular [Tier 3 - In Vitro] - Reduces inflammatory cytokine expression in perifollicular tissue - Follicular inflammation (microinflammation) contributes to AGA progression — reducing it helps preserve follicles - Synergistic with biochanin A (red clover isoflavone) which provides additional 5AR inhibition and anti-inflammatory effects
Practitioner Guide
## Clinical Positioning Acetyl-tetrapeptide-3 is the peptide component of Capixyl, a hair loss ingredient developed by Lucas Meyer Cosmetics. It is exclusively a TOPICAL ingredient — not injectable. It serves as a gentler, non-systemic alternative to finasteride for addressing androgenetic alopecia through local anti-DHT and ECM-supportive mechanisms. ## Formulation Guide ### Concentration - Standard effective concentration: 1-5% acetyl-tetrapeptide-3 in topical solution - Capixyl complex (as sold): typically supplied as 1% active in water/glycol base - In finished products: 2-5% Capixyl complex (which contains the peptide + biochanin A) ### How to Formulate a Topical Serum Base options: - Water-based: distilled water + hyaluronic acid (0.1-0.5%) + preservative (phenoxyethanol 0.5-1%) - Propanediol/glycol base: better stability for peptides, good scalp feel - Alcohol-free is preferred (alcohol can denature peptides and irritate scalp) Simple formulation: - Capixyl complex: 5% - Propanediol: 10% - Panthenol (pro-vitamin B5): 2% - Niacinamide: 2% - Phenoxyethanol: 0.8% - Purified water: QS to 100% Application: 1mL applied to scalp (areas of thinning) once daily, preferably at night. Massage in for 30 seconds. Do not rinse. ### Combining with Minoxidil - Acetyl-tetrapeptide-3 can be added to minoxidil 5% solution - Apply minoxidil (AM or PM) and peptide serum at the alternate time, OR combine in one formulation - Minoxidil addresses blood flow to follicle; peptide addresses ECM and DHT — complementary mechanisms - Many commercial products now combine both (e.g., DS Laboratories Spectral series) ### Combining with Finasteride (Topical) - Topical finasteride (0.025-0.1%) + acetyl-tetrapeptide-3: dual DHT-reduction approach (systemic vs. local 5AR inhibition) - The peptide adds ECM support that finasteride does not provide - Particularly useful for patients who want finasteride benefits but fear systemic side effects — topical formulation reduces systemic exposure ### Combining with Other Hair Peptides The "peptide hair stack" (topical): - Acetyl-tetrapeptide-3 (anti-DHT, ECM support) - AHK-Cu (copper tripeptide — follicle stimulation, angiogenesis) - Biotinoyl-tripeptide-1 (anchoring, follicle metabolism) - Myristoyl-pentapeptide-17 (keratin upregulation) All four can be combined in a single serum at their respective effective concentrations. ## Realistic Expectations - Month 1-2: reduced hair shedding (telogen count decrease) - Month 3-4: early evidence of vellus hair thickening - Month 4-6: noticeable improvement in hair density and thickness in responders - Month 6-12: continued improvement; maximum results at 12 months - Maintenance: continued use required to maintain results - Efficacy: moderate — do not position as equivalent to oral finasteride. Better for mild-moderate thinning. Severe AGA needs pharmaceutical intervention. ## Who Benefits Most - Mild to moderate androgenetic alopecia (Norwood 2-4, Ludwig I-II) - Patients who refuse oral finasteride due to side effect concerns - Women with AGA (finasteride is contraindicated in women of childbearing age; topical peptides are safe) - As an adjunct to minoxidil for enhanced results - Post-hair transplant to support graft survival and existing hair preservation
Research Summary
## Tier 1 — Limited Human Data - Small clinical study (Lucas Meyer data): Capixyl applied topically for 4 months showed 46% increase in anagen/telogen ratio and improved hair density vs. placebo - Industry-sponsored data (not peer-reviewed in major journals) — interpret with appropriate skepticism - No large-scale independent RCTs ## Tier 2 — In Vitro/Ex Vivo Data - Dermal papilla cell cultures: acetyl-tetrapeptide-3 increased cell size by 20-30% and ECM protein expression - Hair follicle organ culture: improved follicle elongation and reduced catagen entry - 5-alpha-reductase inhibition confirmed in enzyme assays (weaker than finasteride but present) - Synergy with biochanin A demonstrated in combined assays ## Tier 3 — Mechanistic - Tetrapeptide sequence interacts with ECM-remodeling integrins on dermal papilla cells - Acetylation improves membrane penetration and stability - TGF-beta suppression reduces the key signal driving follicular miniaturization in AGA ## Evidence Gaps - No independent, large-scale, peer-reviewed RCTs - Dose-response not rigorously characterized in humans - Long-term efficacy (>12 months) not studied - Comparison with minoxidil or finasteride as monotherapy not available - Most evidence comes from ingredient manufacturer — potential bias